daraxonrasib
PulseAugur coverage of daraxonrasib — every cluster mentioning daraxonrasib across labs, papers, and developer communities, ranked by signal.
- 2026-08-26 product_launch The FDA approved daraxonrasib (Rasonque) as a new targeted therapy for pancreatic cancer. source
- 2026-06-08 product_launch Daraxonrasib showed significant positive results in a Phase 3 trial for pancreatic cancer, doubling survival duration. source
- 2026-05-31 research_milestone A new drug, daraxonrasib, demonstrated a significant increase in survival time for advanced pancreatic cancer patients in a clinical trial. source
2 day(s) with sentiment data
-
Pancreatic Cancer Drug Daraxonrasib Shows Promise for Lung Cancer Patients
A targeted cancer drug, Daraxonrasib, has shown promising results in new trials, suggesting it may also be effective in treating certain cases of lung cancer. This development expands the potential applications of the d…
-
FDA approves Revolution Medicines' pancreatic cancer pill Rasonque
The FDA has approved Rasonque, a new daily pill from Revolution Medicines, designed to target RAS protein mutations that drive tumor growth in pancreatic cancer. This approval marks a significant breakthrough, as it val…
-
FDA approves new pancreatic cancer drug daraxonrasib after trial success
The U.S. FDA has approved daraxonrasib (Rasonque), a new targeted therapy for pancreatic ductal adenocarcinoma (PDAC) in adults whose disease has spread and failed other treatments. This marks a significant advancement …
-
Revolution Medicines' cancer drug shows promise, sparking debate on US innovation model
A new drug, daraxonrasib from Revolution Medicines, has shown unprecedented success in nearly doubling survival rates for pancreatic cancer patients, eliciting a strong positive reaction from the medical community. This…
-
RAS-targeted therapies show promise for new cancer treatments
CITIC Securities has released a research report highlighting the potential of RAS-targeted therapies in oncology. These therapies aim to unlock previously undruggable targets within the RAS gene family, which includes K…
-
New antibody treatment targets hard-to-reach pancreatic cancer protein
Researchers have developed a novel experimental treatment for pancreatic cancer that targets a difficult-to-reach protein deep within cells. This new approach uses carrier particles to deliver antibodies inside the cell…
-
Daraxonrasib doubles survival for pancreatic cancer patients
Daraxonrasib, a new drug developed by Revolution Medicines, has shown significant promise in treating pancreatic ductal adenocarcinoma, a notoriously deadly cancer. In a Phase 3 trial, the drug doubled survival duration…
-
Experimental pill nearly doubles survival for advanced pancreatic cancer
A new experimental pill, daraxonrasib, has shown significant promise in treating advanced pancreatic cancer by targeting a mutated protein that fuels tumor growth. In a study, patients taking the daily pill nearly doubl…